Related Experiment Video
Updated: Sep 21, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Inhibitors of EYA3 Protein in Ewing Sarcoma
Fahad Hassan Shah1, Song Ja Kim1
1Department of Biological Sciences, College of Natural Sciences, Kongju National University, Gongju 32588, Republic of Korea.
Objective:
Among sarcomas, Ewing sarcoma (EWS) is characterized as a highly malignant type of bone tumor caused by the fusion of EWS RNA Binding Protein-1 (EWSR1)/ Friend leukemia integration 1 (FLI1) genes. The product of fusion gene gives rise to EWSR1/FLI1 which activates the activity of Eyes absent homolog 3 (EYA3) which causes tumor growth and angiogenesis. EYA3 is now considered as a therapeutic drug target for EWS . The study was designed to gather potential inhibitors for the EYA3 target using medicinal compounds.
Methods:
In this study, we have obtained a list of medicinal compounds from the NuBBE database and downloaded their structural information. Then insilico screening analysis of >2,000 medicinal compounds was performed with PyRX virtual drug screening software to discover potential inhibitors for the treatment of EWS.
Results:
Our investigation revealed that Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione show interactive affinity for EYA3 active residues. Moreover, these compounds have adequate toxicity, can induce cytotoxicity in EWS cells, and are capable of regulating the expression of genes activated by EWSR1/FLI1.
Conclusion:
Our study concluded that Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione are promising drug candidates for the treatment of EWS and should be further subjected to invitro testing.
Insights
Researchers identified Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione as potential inhibitors for Eyes absent homolog 3 (EYA3). These compounds show promise for treating Ewing sarcoma (EWS) by targeting the EWSR1/FLI1 fusion gene
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ewing sarcoma (EWS) is a highly malignant bone tumor driven by the EWSR1/FLI1 gene fusion.
- The EWSR1/FLI1 fusion protein activates Eyes absent homolog 3 (EYA3), promoting tumor growth and angiogenesis.
- EYA3 is recognized as a critical therapeutic target for EWS treatment.
Purpose of the Study:
- To identify potential EYA3 inhibitors using medicinal compounds.
- To discover novel therapeutic strategies for Ewing sarcoma.
Main Methods:
- In silico screening of over 2,000 medicinal compounds from the NuBBE database using PyRX software.
- Evaluation of compound structural information and binding affinity to EYA3 active residues.
Main Results:
- Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione demonstrated significant binding affinity to EYA3.
- These compounds exhibited adequate toxicity and induced cytotoxicity in EWS cells.
- The identified compounds were capable of regulating gene expression influenced by EWSR1/FLI1.
Conclusions:
- Sorbifolin and 1,7-Dihydroxy-3-methylanthracene-9.10-dione are promising drug candidates for EWS treatment.
- Further in vitro testing is recommended to validate their therapeutic potential.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Mitogens and the Cell Cycle
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Inhibition of Cdk Activity

